ALKEM LABORATORIES LTD.

The Q1 FY2027 earnings conference call for Alkem Laboratories Limited, held on August 14, 2026, featured management discussing the company's financial performance. Management reported a revenue from operations of INR 3,740 crores, reflecting an 11% year-on-year growth, with India sales at INR 2,497 crores (10.3% growth) and international sales at INR 1,222 crores (16% growth). The EBITDA margin was noted at 20.5%, a 3.7% increase year-on-year. However, net profit saw a decline of 21.7% due to taxation issues. Management highlighted outperformance in key therapy segments compared to the Indian pharmaceutical market. They also addressed challenges in the Trade Generics segment and provided updates on regulatory matters regarding their U.S. operations. The call concluded with management expressing confidence in their strategic execution despite external challenges.

Management presented a balanced view of performance, highlighting both achievements and challenges.